Rituximab
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
Explore 27 assets in Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05032183CT.gov Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT03808610CT.gov Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | M.D. Anderson Cancer Center | P1/2 | CCC · 48 |
| Dexasone | Princess Maxima Center for Pediatric Oncology | P1/2 | CCC |
| Prednisolone | Children's Oncology Group | P1/2 | CCC |
| Hydrocortisone | Children's Oncology Group | P1/2 | CCC |
| Prednisone | M.D. Anderson Cancer Center | P1/2 | CCC |
| Nelarabine | M.D. Anderson Cancer Center | P1/2 | CCC |
| Obi 3424 | SWOG Cancer Research Network | P1/2 | CCC |
| Vincristine Sulfate | ECOG-ACRIN Cancer Research Group | P1/2 | CCC |
| Mercaptopurine Anhydrous | M.D. Anderson Cancer Center | P1/2 | CCC |
+26 more in the Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-refractory-precursor-t-lymphoblastic-lymphomaleukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →